


## Amendments to the Claims

The following listing of claims replaces all prior listings of claims in the application.

**Listing of Claims**

1. (previously presented) A compound according to Formula I:



wherein,

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;

n is 1;


R<sup>1</sup> is -H, -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, -CN, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl or halo(C<sub>1</sub>-C<sub>6</sub>)alkyl;

the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*;

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-;


\* indicates that, when R<sup>1</sup> is other than -H, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound.

2. (previously presented) A compound according to claim 1 of Formula Iz:




or a salt thereof.

3. (previously presented) A compound according to claim 1 of the Formula Ie:



or a salt thereof.

4. (previously presented) A compound according to claim 1 of Formula IA:



wherein:

A<sup>1</sup> is aryl or heteroaryl; and x is 0, 1, 2, 3, 4 or 5,

either B<sup>1</sup> is aryl and y is 1, 2, 3, 4 or 5, or B<sup>1</sup> is heteroaryl and y is 0, 1, 2, 3, 4 or 5;

provided that x does not exceed the number of substitutable positions of the ring to which each R<sup>a</sup> is attached; and y does not exceed number of substitutable positions of the ring to which each R<sup>b</sup> is attached;

each R<sup>a</sup> is independently selected from the group consisting of halogen; -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, -C(=O)R<sup>2</sup>, -NR<sup>2</sup><sub>2</sub>, -NHC(=O)R<sup>3</sup>, -NHSO<sub>2</sub>R<sup>3</sup>, -NHR<sup>4</sup>, -NHCR<sup>2</sup>R<sup>4</sup>C(=O)R<sup>6</sup>, -C(=O)OR<sup>2</sup>, -C(=O)NHR<sup>2</sup>; -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -P(=O)(OH)<sub>2</sub>, dimethylamino(C<sub>2</sub>-C<sub>6</sub>)alkoxy, -NHC(=NH)NHR<sup>2</sup>, -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl, -(C<sub>1</sub>-C<sub>6</sub>)haloalkoxy and -N=CH-R<sup>7</sup>;

each R<sup>b</sup> is independently selected from the group consisting of -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, -C(=O)R<sup>2</sup>, halogen, -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -C(=O)OR<sup>2</sup>, -NR<sup>2</sup><sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)haloalkyl and (C<sub>1</sub>-C<sub>6</sub>)haloalkoxy;

each R<sup>2</sup> is independently selected from the group consisting of -H and -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl;

each R<sup>3</sup> is independently selected from the group consisting of -H, -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, -O(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, substituted and unsubstituted aryl, substituted heterocyclyl(C<sub>1</sub>-C<sub>3</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)heteroalkyl, -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl, -CR<sup>2</sup>R<sup>4</sup>NHR<sup>5</sup>, -N(R<sup>2</sup>)<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkyleneNH<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkylene-N(CH<sub>3</sub>)<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkylene-N(CH<sub>3</sub>)<sub>2</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkylene-N<sup>+</sup>((C<sub>1</sub>-C<sub>3</sub>)alkyl)<sub>3</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkylene-N<sup>+</sup>(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>3</sub>, -(C<sub>1</sub>-C<sub>3</sub>)alkylene-OR<sup>2</sup>, -(C<sub>1</sub>-C<sub>4</sub>)alkylene-CO<sub>2</sub>R<sup>2</sup>, -(C<sub>1</sub>-C<sub>4</sub>)alkylene-C(=O)halogen, halo(C<sub>1</sub>-C<sub>3</sub>)alkyl-, -(C<sub>1</sub>-C<sub>3</sub>)alkylene-C(=O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, and -(C<sub>1</sub>-C<sub>4</sub>)perfluoroalkylene-CO<sub>2</sub>R<sup>2</sup>;

each R<sup>4</sup> is independently selected from the group consisting of -H, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(CH<sub>2</sub>)<sub>3</sub>-NH-C(NH<sub>2</sub>)(=NH), -CH<sub>2</sub>C(=O)NH<sub>2</sub>, -CH<sub>2</sub>COOH, -CH<sub>2</sub>SH, -(CH<sub>2</sub>)<sub>2</sub>C(=O)-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>COOH, -CH<sub>2</sub>-(2-imidazolyl), -(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>-S-CH<sub>3</sub>, phenyl, -CH<sub>2</sub>-phenyl, -CH<sub>2</sub>-OH, -CH(OH)-CH<sub>3</sub>, -CH<sub>2</sub>-(3-indolyl), and -CH<sub>2</sub>-(4-hydroxyphenyl);

each R<sup>5</sup> is independently selected from the group consisting of -H and a carboxy terminally linked peptidyl residue containing from 1 to 3 amino acids in which the terminal amino group of the peptidyl residue is present as a functional group selected from the group consisting of -NH<sub>2</sub> and -NHC(=O)(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NH(C<sub>1</sub>-C<sub>6</sub>)alkyl, -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub> and -NHC(=O)O(C<sub>1</sub>-C<sub>7</sub>)hydrocarbyl;

each R<sup>6</sup> is independently selected from the group consisting of -OR<sup>2</sup> and an N-terminally linked peptidyl residue containing from 1 to 3 amino acids in which the terminal carboxyl group of the peptidyl residue is present as a functional group selected from the group consisting of -CO<sub>2</sub>R<sup>2</sup> and -C(=O)NR<sup>2</sup><sub>2</sub>; and


each R<sup>7</sup> is independently selected from the group consisting of substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl or a salt of such a compound.

5. (previously presented) A compound according to claim 4, or a salt thereof, wherein the sum of x and y is greater than zero.

6. (previously presented) A compound according to claim 5, or a salt thereof, wherein A<sup>1</sup> is an aryl radical.

7. (previously presented) A compound according to claim 6 selected from the group consisting of: (1E)-2-(4-fluorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-bromophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(2-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(3-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; and (1E)-2-(4-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene.


8. (previously presented) A compound according to claim 6, of Formula IB:



or a salt thereof.

9. (previously presented) A compound according to claim 8, or a salt thereof, wherein each R<sup>a</sup> is independently selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -NO<sub>2</sub>, -CN, -C(=O)OR<sup>2</sup>, -OH, -NH<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)trifluoroalkoxy and -CF<sub>3</sub>.

10. (previously presented) A compound according to claim 9, of Formula IC:



or a salt thereof.

11. (previously presented) A compound according to claim 10 wherein each R<sup>a</sup> and each R<sup>b</sup> is independently selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -NO<sub>2</sub>, -CN and -CF<sub>3</sub>.
12. (previously presented) A compound according to claim 10, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is *E*.
13. (previously presented) A compound according to claim 12, or a salt thereof, wherein x is 0, 1 or 2 and y is 1 or 2.
14. (previously presented) A compound according to claim 12 selected from the group consisting of: (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(3-hydroxy-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(4-methoxy-3-nitrophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; 2-({[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}-methyl)-2-methoxyphenyl]amino}sulfonyl)acetic acid; 2-{*N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetic acid; [5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminocarboxamide; 2-{[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}acetic acid; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-dinitrophenyl)carboxamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-diaminophenyl)carboxamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]2-chloroacetamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(4-methylpiperazinyl)acetamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]benzamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl](4-nitrophenyl)carboxamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](4-aminophenyl)carboxamide; *N*-[5-([(1E)-2-(2,4,6-trimethoxyphenyl)

vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2,6-diaminohexanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2-amino-3-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2S)-2-amino-3-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminamide; (1E)-1-({[4-methoxy-3-(methylamino)phenyl]methyl}sulfinyl)-2-(2,4,6-trimethoxyphenyl)ethene; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]acetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-dinitrophenyl)sulfonyl]amine; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-diaminophenyl)sulfonyl]amine; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(dimethylamino)-acetamide; 2-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}propanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl][4-(4-methylpiperazinyl)phenyl]carboxamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxyacetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-pyridylacetamide; {*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}methyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(triethylamino)acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]-2-[tris(2-hydroxyethyl)amino]acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxy-2-methylpropanamide; 1-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-isopropyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2,2,2-trifluoroacetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(trifluoro-

methyl)sulfonyl]amine;                   3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}propanoic acid; 3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}propanoyl chloride;       3-[({*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}methyl)oxygenyl]propanoic acid;   4-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}butanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(phosphonoxy)acetamide, disodium salt;   4-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}butanoic acid; 3-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}propanoic acid;                   *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]methoxycarboxamide;                   [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(4-methoxyphenyl)sulfonyl]amine; {*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}ethyl acetate;                   methyl-3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}propanoate; ethyl-2-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetate;                   *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2,2,3,3,3-pentafluoropropanamide; methyl-2-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetate;                   3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2,3,3-tetrafluoropropanoic acid;                   *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-aminoacetamide; 2-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(dimethylamino)-2,2-difluoroacetamide,                   4-((1E)-2-{[(4-fluorophenyl)methyl]sulfinyl}vinyl)benzoic acid; 4-((1E)-2-{[(4-iodophenyl)methyl]-

sulfinyl} vinyl)benzoic acid; 4-((1E)-2-{{(4-chlorophenyl)methyl}sulfinyl} vinyl)benzoic acid; 1-[5-((1E)-2-{{(4-chlorophenyl)methyl}sulfinyl} vinyl)-2-fluoro-phenyl]-2-(dimethylamino)ethan-1-one; (1E)-2-(2,4-difluorophenyl)-1-{{(4-bromophenyl)methyl}sulfinyl}ethene; (1E)-2-(3-amino-4-fluorophenyl)-1-{{(4-chlorophenyl)methyl}sulfinyl}ethene; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl}sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{(4-bromophenyl)methyl}sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-{{(2,3,4,5,6-pentafluorophenyl)methyl}sulfinyl}ethene; (1E)-2-(4-chlorophenyl)-1-{{(2,3,4,5,6-pentafluorophenyl)methyl}sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{{(2,3,4,5,6-pentafluorophenyl)methyl}sulfinyl}ethene; (1E)-1-{{(3,4-dichlorophenyl)methyl}sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{(4-iodophenyl)methyl}sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-{{(4-bromophenyl)methyl}sulfinyl}-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl}sulfinyl}-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-{{(2,4-dichlorophenyl)methyl}sulfinyl}-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(3-methyl-2,4-dimethoxyphenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(3,4,5-trimethoxyphenyl)ethene; (1E)-1-{{(2-nitro-4,5-dimethoxyphenyl)methyl}sulfinyl}-2-(3,4,5-trimethoxyphenyl)ethene; (1E)-1-{{(2-nitro-4,5-dimethoxyphenyl)methyl}sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{{(2-nitro-4,5-dimethoxyphenyl)methyl}sulfinyl}-2-(3-methyl-2,4-dimethoxyphenyl)ethene; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(2,3,4-trifluorophenyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl}sulfinyl}-2-(2,3,4-trifluorophenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(2,6-methoxy-4-hydroxyphenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(2,3,5,6-tetrafluorophenyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl}sulfinyl}-2-(2,4,5-trimethoxyphenyl)ethene;

methoxyphenyl)methyl]sulfinyl}-2-(2,3,4-trimethoxyphenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3-nitro-4-hydroxy-5-methoxyphenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3,4-dimethoxy-6-nitrophenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3,4-dimethoxy-5-iodophenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(2,6-dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(2-hydroxy-4,6-dimethoxyphenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethylphenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2,6-dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-hydroxy-4,6-dimethoxyphenyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2,6-dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(2,4,6-trimethoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(2,3,4-trimethoxyphenyl)methyl]sulfinyl}-2-(2,6-dimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(2,6-dimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-({[4-(trifluoromethyl)phenyl]methyl}-sulfinyl)ethene; (1E)-2-(4-chlorophenyl)-1-({[4-(trifluoromethyl)phenyl]methyl}-sulfinyl)ethene; (1E)-2-(4-bromophenyl)-1-({[4-(trifluoromethyl)phenyl]methyl}-sulfinyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-chloro-phenyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(4-fluoro-phenyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(4-chloro-phenyl)ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-nitrophenyl)methyl]sulfinyl}-ethene; 4-({[(1E)-2-(4-fluorophenyl)vinyl]-sulfinyl}methyl)benzene-carbonitrile; 4-({[(1E)-2-(4-chlorophenyl)vinyl]sulfinyl}-methyl)benzene-carbonitrile; 4-({[(1E)-2-(4-bromophenyl)vinyl]sulfinyl}-

methyl)benzene-carbonitrile; (1E)-2-(3,4-difluorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(3-chloro-4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-chloro-4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2,4-dichlorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(3,4-dichlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2,3-dichlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-iodophenyl)methyl]-sulfinyl}ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)-ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(2-nitrophenyl)-ethene; (1E)-2-(4-iodophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-2-(3,4-dichlorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-fluorophenyl)methyl]-sulfinyl}-ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene;

methyl]sulfinyl}ethene; (1E)-2-(3-methyl-4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-cyanophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-cyanophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-cyanophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-chlorophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-chlorophenyl)-1-{[(4-nitrophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-nitrophenyl)methyl]sulfinyl}ethene; and salts thereof.

15. (previously presented) A compound according to claim 10 wherein:

$R^a$  is selected from the group consisting of chlorine, fluorine and bromine, and said  $R^a$  is bonded to the para position of the ring to which it is attached;

$x$  is 0 or 1;


R<sup>b</sup> is selected from the group consisting of chlorine, fluorine, bromine, methyl and methoxy, and said R<sup>b</sup> is bonded to the ortho or para position of the ring to which it is bonded; and

y is 1, 2 or 3.

16. (previously presented) A compound according to claim 15 wherein the configuration of the substituents on the carbon-carbon double bond is E-.
17. (previously presented) A compound according to claim 16 selected from the group consisting of: (1E)-2-(2-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-chlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2,4-difluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-bromophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; and (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)ethene.
18. (previously presented) A compound according to claim 10, or a salt thereof, wherein:  
each R<sup>a</sup> and each R<sup>b</sup> is independently selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen and nitro, and is bonded to the ortho or para position of the ring to which it is attached;  
x is 0, 1, 2 or 3; and  
y is 1, 2 or 3.
19. (previously presented) A compound according to claim 18, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is Z-.

20. (previously presented) A compound according to claim 19 selected from the group consisting of: (1Z)-2-(4-chlorophenyl)-1-[benzylsulfinyl]ethene; (1Z)-2-(4-chlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1Z)-2-(4-chlorophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}-ethene; (1Z)-2-(4-chlorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-[benzylsulfinyl]ethene; (1Z)-2-(4-bromophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-methylphenyl)-1-[benzylsulfinyl]ethene; (1Z)-2-(4-methylphenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-methylphenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-methylphenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; and (1Z)-2-(4-fluorophenyl)-1-{[(4-iodophenyl)methyl]sulfinyl}ethene.

21. (previously presented) A compound according to claim 5, of Formula ID:



wherein B<sup>2</sup> is selected from the group consisting of heteroaryl and aryl other than phenyl

or a salt thereof.

22. (previously presented) A compound according to claim 21, or a salt thereof, wherein B<sup>2</sup> is heteroaryl.

23. (previously presented) A compound according to claim 21, or a salt thereof, wherein B<sup>2</sup> is selected from the group consisting of furyl, thienyl, pyrrolyl, thiazolyl, pyridyl, thienyl-1-dioxide, anthryl, and naphthyl.

24. (previously presented) A compound according to claim 23, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is E-.

25. (previously presented) A compound according to claim 24, or a salt thereof, wherein R<sup>a</sup> is independently selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, -CN, -NO<sub>2</sub>, and -CF<sub>3</sub>.

26. (original) A compound of claim 25 selected from the group consisting of: (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-2-(4-bromo(2-thienyl))-1-{[(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-bromophenyl)methyl]-sulfinyl}ethene; 2-((1E)-2-{[(4-fluorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{[(4-chlorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{[(4-bromophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-

{[(4-bromophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-methylphenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-trifluoromethylphenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-cyanophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-nitrophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; 3-((1E)-2-{[(4-fluorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-chlorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-bromophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-methoxyphenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-furyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-furyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-methylphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-trifluoromethylphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-cyanophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-nitrophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(1,3-thiazol-2-yl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-pyrrol-2-yethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-pyrrol-2-yethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-

2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-2-(9-anthryl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; and salts thereof.

27. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
28. (withdrawn) A conjugate of the Formula, I-L-Ab;  
wherein:  
I is a compound according to claim 1 or a pharmaceutically acceptable salt thereof;  
Ab is an antibody; and  
-L- is a single covalent bond or a linking group covalently linking said compound to said antibody.
29. (withdrawn) A conjugate according to claim 28 wherein said antibody Ab is a monoclonal antibody or a monospecific polyclonal antibody.
30. (withdrawn) A conjugate according to claim 29 wherein said antibody Ab is a tumor-specific antibody.

31. (withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one conjugate according to claim 28.
32. (previously presented) A method of treating an individual for breast cancer, prostate cancer, lung cancer or colorectal cancer comprising administering to said individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
33. (canceled)
34. (canceled)
35. (canceled)
36. (currently amended) A method of treating an individual for a cancer selected from the group consisting of ovarian, breast, prostate, testicular, lung, renal, and colorectal skin, and brain cancers, ~~or the cancer is a leukemia~~, comprising administering to said individual an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and administering an effective amount of therapeutic ionizing radiation to the individual.
37. (previously presented) A method of inducing apoptosis of tumor cells in an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer comprising administering to said individual an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
38. (canceled)
39. (withdrawn) A method of treating an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer, comprising administering to said individual an effective amount of at least one conjugate according to claim 28.

40. (canceled)

41. (canceled)

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

64. (canceled)

65. (canceled)


66. (canceled)

67. (canceled)

68. (canceled)

69. (previously presented) A process for preparing a compound according to claim 3 comprising:


(a) reacting a compound of Formula II:



wherein A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

n is 1; and

$R^1$  is  $-H$ ,  $-(C_1-C_8)$ hydrocarbyl,  $-CN$ ,  $-CO_2(C_1-C_6)$ alkyl or halo( $C_1-C_6$ )alkyl;  
with a compound of Formula III:




wherein B is substituted aryl or substituted or unsubstituted heteroaryl; and

(b) isolating a compound according to claim 3 from the reaction products.

70. (withdrawn) A process according to claim 69 wherein the compound of Formula II is prepared by;

(a) reacting a compound of Formula IIA:




with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and

(b) isolating a compound of Formula II from the reaction products.

71. (withdrawn) A process according to claim 70 wherein the compound of Formula IIA is prepared by:

(a) reacting a compound of Formula IIB:



wherein:


L is a leaving group;

with mercaptoacetic acid; and

(b) isolating a compound of Formula IIA from the reaction products.

72. (withdrawn) A process for preparing a compound according to claim 2 comprising:

(a) reacting a compound of Formula IV:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;

n is 1; and


R<sup>1</sup> is -H, -(C<sub>1</sub>-C<sub>8</sub>)hydrocarbyl, -CN, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl or halo(C<sub>1</sub>-C<sub>6</sub>)alkyl;

with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and


(b) isolating a compound according to claim 2 from the reaction products.

73. (withdrawn) A process according to claim 72 wherein the compound of Formula IV is prepared by:

(a) reacting a compound of Formula IVA:




wherein  $Q^+$  is a counterion selected from the group consisting of alkali metals, alkaline earth metals and transition metals;  
with a compound of Formula IVB:



; and

(b) isolating a compound of Formula IV from the reaction products.

74. (withdrawn) A process for preparing a compound according to Formula V:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;


n is 1;

 $\text{R}^1$  is  $-\text{H}$ ,  $-(\text{C}_1\text{-C}_8)$ hydrocarbyl,  $-\text{CN}$ ,  $-\text{CO}_2(\text{C}_1\text{-C}_6)$ alkyl or halo( $\text{C}_1\text{-C}_6$ )alkyl;the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*;- and

\* indicates that, when  $\text{R}^1$  is other than  $-\text{H}$ , the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound;

comprising the steps of:

(a) reacting a compound according to Formula I:



wherein A, B, n, R<sup>1</sup> and \* are so defined;

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;  
the configuration of the substituents on the carbon-carbon double bond is either *E*-  
or *Z*; and

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any  
mixture of R- and S-; or a salt thereof;

with an oxidizing agent capable of oxidizing a sulfoxide to a sulfone; and

(b) isolating a compound according to Formula V from the reaction products.

75. (canceled)

76. (canceled)

77. (previously presented) An isolated optical isomer of a compound according to claim 1, or  
a salt thereof.